GlobeNewswire Inc.··Pomerantz LlpPomerantz Initiates Securities Investigation into Pharming Group Following FDA Rejection
Pomerantz Law Firm investigates Pharming Group after FDA rejects pediatric drug application, causing 17% stock decline. Inquiry focuses on whether regulatory risks were adequately disclosed to investors.
PHARsecurities fraudclass action lawsuit